Tarsons Products Limited announced the outcome of its Board Meeting held on February 06, 2026. The Board approved the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. In a significant move, the company approved an equity infusion of EUR 3 Million (approximately ₹27 Crore) into its wholly-owned Singapore subsidiary, Tarsons Life Science Pte. Ltd., to meet operational and financial expenses. This capital infusion is planned to be completed in quarterly tranches by March 31, 2027. Furthermore, the Board approved the appointment of Mr. Vinesh Mohan Kriplani as an Additional Director (Non-Executive Independent Director) effective February 06, 2026, for a term of five years, subject to shareholder approval. Mr. Kriplani brings over 29 years of experience in corporate and international taxation, M&A, and restructuring. Concurrently, Mr. Girish Paman Vanvari resigned as an Independent Director, effective February 06, 2026, due to personal commitments. Following these changes, the Board reconstituted its Audit Committee, Nomination and Remuneration Committee, and Risk Management Committee.
